SPY001

DRUG2 trials

Sponsors

Spyre Therapeutics, Inc.

Conditions

ColitisColitis, UlcerativeInflammatory Bowel DiseasesUlcerative Colitis

Phase 2

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

RecruitingNCT07012395

Spyre Therapeutics, Inc.Colitis, Colitis, Ulcerative, Inflammatory Bowel Diseases +1

Start: 2025-05-27End: 2028-03-01Target: 645Updated: 2026-08-25

Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

Enrolling by invitationNCT07652294

Spyre Therapeutics, Inc.Colitis, Colitis, Ulcerative, Inflammatory Bowel Diseases +1

Start: 2026-06-08End: 2030-01-03Target: 645Updated: 2026-09-15